OSI Pharmaceuticals, Inc.: Data from the Phase III SATURN Study Show Tarceva Improved Progression-Free Survival When Used as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer

MELVILLE, N.Y.--(BUSINESS WIRE)--Eighth graph, third sentence should read: Fifty-five percent of patients in the Tarceva arm and 64% of patients on placebo received subsequent therapy after progressing. (sted Sixty-four percent of patients in the Tarceva arm and 55% of patients on placebo received subsequent therapy after progressing.)